These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

332 related articles for article (PubMed ID: 31899993)

  • 41. Pembrolizumab vs the EXTREME Regimen in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: A Cost-Effectiveness Analysis.
    Lang Y; Dong D; Wu B
    Clin Drug Investig; 2020 Dec; 40(12):1137-1146. PubMed ID: 33095408
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Current status of systemic therapy for recurrent and/or metastatic squamous cell carcinoma of the head and neck.
    Jacob LA; Chaudhuri T; Lakshmaiah KC; Babu KG; Dasappa L; Babu M; Rudresha AH; Lokesh KN; Rajeev LK
    Indian J Cancer; 2016; 53(4):471-477. PubMed ID: 28485332
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Afatinib in squamous cell carcinoma of the head and neck.
    Specenier P; Vermorken J
    Expert Opin Pharmacother; 2016 Jun; 17(9):1295-301. PubMed ID: 27160335
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The role of CD73 in predicting the response to immunotherapy in head and neck cancer patients.
    Botticelli A; Cirillo A; d'Amati G; Di Gioia C; Corsi A; Della Rocca C; Santini D; Carletti R; Pisano A; Polimeni A; De Vincentiis M; Valentini V; di Cristofano C; Romeo U; Cerbelli E; Messineo D; De Felice F; Leopizzi M; Cerbelli B
    Pathol Res Pract; 2024 Aug; 260():155415. PubMed ID: 38996615
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Impact of locoregional irradiation in patients with upfront metastatic head and neck squamous cell carcinoma.
    Rambeau A; Bastit V; Thureau S; Thariat J; Moldovan C; Roge M; Babin E; Gery B; Di Fiore F; Florescu C; Clatot F
    Oral Oncol; 2019 Jun; 93():46-51. PubMed ID: 31109695
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Efficacy and toxicity of cetuximab with chemotherapy in recurrent and metastatic head and neck cancer: A prospective observational study.
    Tiwari S; Goel V; John MC; Patnaik N; Doval DC
    Indian J Cancer; 2016; 53(4):487-492. PubMed ID: 28485336
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Response to salvage chemotherapy after progression on immune checkpoint inhibitors in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck.
    Saleh K; Daste A; Martin N; Pons-Tostivint E; Auperin A; Herrera-Gomez RG; Baste-Rotllan N; Bidault F; Guigay J; Le Tourneau C; Saada-Bouzid E; Even C
    Eur J Cancer; 2019 Nov; 121():123-129. PubMed ID: 31574417
    [TBL] [Abstract][Full Text] [Related]  

  • 48. A comparison of weekly paclitaxel and cetuximab with the EXTREME regimen in the treatment of recurrent/metastatic squamous cell head and neck carcinoma.
    Nakano K; Marshall S; Taira S; Sato Y; Tomomatsu J; Sasaki T; Shimbashi W; Fukushima H; Yonekawa H; Mitani H; Kawabata K; Takahashi S
    Oral Oncol; 2017 Oct; 73():21-26. PubMed ID: 28939072
    [TBL] [Abstract][Full Text] [Related]  

  • 49. A Q-TWiST Analysis Comparing Nivolumab and Therapy of Investigator's Choice in Patients with Recurrent/Metastatic Platinum-Refractory Squamous Cell Carcinoma of the Head and Neck.
    Cocks K; Contente M; Simpson S; DeRosa M; Taylor FC; Shaw JW
    Pharmacoeconomics; 2019 Aug; 37(8):1041-1047. PubMed ID: 30972702
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Clinical outcomes with therapies for previously treated recurrent/metastatic head-and-neck squamous cell carcinoma (R/M HNSCC): A systematic literature review.
    Lala M; Chirovsky D; Cheng JD; Mayawala K
    Oral Oncol; 2018 Sep; 84():108-120. PubMed ID: 30115469
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Nivolumab in squamous cell carcinoma of the head and neck.
    Specenier P
    Expert Rev Anticancer Ther; 2018 May; 18(5):409-420. PubMed ID: 29560755
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Docetaxel, cisplatin, and fluorouracil for patients with inoperable recurrent or metastatic head and neck squamous cell carcinoma.
    Cho H; Nishiike S; Yamamoto Y; Takenaka Y; Nakahara S; Yasui T; Hanamoto A; Inohara H
    Auris Nasus Larynx; 2015 Oct; 42(5):396-400. PubMed ID: 25721854
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Nivolumab in Patients with Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck: Efficacy and Safety in CheckMate 141 by Prior Cetuximab Use.
    Ferris RL; Licitra L; Fayette J; Even C; Blumenschein G; Harrington KJ; Guigay J; Vokes EE; Saba NF; Haddad R; Ramkumar S; Russell J; Brossart P; Tahara M; Colevas AD; Concha-Benavente F; Lynch M; Li L; Gillison ML
    Clin Cancer Res; 2019 Sep; 25(17):5221-5230. PubMed ID: 31239321
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Pembrolizumab alone or with chemotherapy for squamous cell carcinoma of the head and neck: A cost-effectiveness analysis from Chinese perspective.
    Zhou K; Li Y; Liao W; Zhang M; Bai L; Li Q
    Oral Oncol; 2020 Aug; 107():104754. PubMed ID: 32428689
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Advances in pharmacotherapy for head and neck cancer.
    Kumar S; Noronha V; Patil V; Joshi A; Menon N; Prabhash K
    Expert Opin Pharmacother; 2021 Oct; 22(15):2007-2018. PubMed ID: 34187268
    [No Abstract]   [Full Text] [Related]  

  • 56. The Evolving Role of Taxanes in Combination With Cetuximab for the Treatment of Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck: Evidence, Advantages, and Future Directions.
    Guigay J; Tahara M; Licitra L; Keilholz U; Friesland S; Witzler P; Mesía R
    Front Oncol; 2019; 9():668. PubMed ID: 31497530
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Pembrolizumab for the treatment of head and neck squamous cell cancer.
    Ho WJ; Mehra R
    Expert Opin Biol Ther; 2019 Sep; 19(9):879-885. PubMed ID: 31317798
    [No Abstract]   [Full Text] [Related]  

  • 58. Immunotherapy, Chemotherapy, or Both: Options for First-Line Therapy for Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma.
    Ho AL
    J Clin Oncol; 2023 Feb; 41(4):736-741. PubMed ID: 36223554
    [No Abstract]   [Full Text] [Related]  

  • 59. Taxane, platinum and 5-FU prior to chemoradiotherapy benefits patients with stage IV neck node-positive head and neck cancer and a good performance status.
    Lowe NM; Bernstein JM; Mais K; Garcez K; Lee LW; Sykes A; Thomson DJ; Homer JJ; West CM; Slevin NJ
    J Cancer Res Clin Oncol; 2018 Feb; 144(2):389-401. PubMed ID: 29222650
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Palliative weekly chemotherapy along with cetuximab in recurrent and metastatic head and neck cancers: a retrospective analysis.
    Rangaraju RR; Sharma JB; Dewan AK; Anand AK; Sheh R; Jena A; Chaturvedi AK
    Indian J Cancer; 2012; 49(1):1-5. PubMed ID: 22842160
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.